The Administrative Core will provide several essential functions to this program project. (1) The Core will supply grant management services to the five Projects and the Biostatistics Core (Core B) in this program. This Core will provide financial, administrative, clerical, and secretarial services for the Principal Investigator (Tom Look), co-Principal Investigator (Harald von Boehmer), Project Leaders (Peter Sicinski, Fred Alt, Rick Young, Harald von Boehmer and Tom Look), and Core Directors (Donna Neuberg and Tom Look) for Program-related grant activities. These activities include preparation of progress reports, preparation of budgets, communication with the NIH regarding renewals and all financial interactions, assurance that the labs supported by this Program are in compliance with all institutional, state, and federal regulations. This will include working with the investigators at the Immune Diseases Institute and Whitehead Institute, Massachusetts Institute of Technology. (2) The core will be responsible for organizing and coordinating the numerous meetings that will serve as the foundation for scientific interaction and review of the program. These include meetings of the scientific team, of the project leaders and Core Directors, and with members of the External and Internal Advisory boards. Tom Look, the PI of the program project will serve as Director of this Core and scientific director and chief administrator of the Program Project. Harald von Boehmer will serve as Co-Director for the administrative core and as such will act as Co-Investigator for the program project, assisting in administrative aspects of the core and acting as Principal Investigator in Dr. Look's absence. Doris Dodson will be responsible for preparing communications and reports to the NIH, for preparing the grant applications, for setting up the numerous meetings that are part of this Program, and assisting with the travel and agendas of the external reviewers and she will assist Dr. Look with record keeping and she will monitor animal and biosafety protocols involved in the Program and help prepare annual noncompeting progress reports for the NCI.
Successful completion of this 5-year renewal of our program will improve understanding of how T-cell regulatory pathways are disrupted to initiate and maintain the transformed phenotype in T-ALL and T-LBL, with the long-term goal to pinpoint genes whose inhibition could lead to the development of new and highly specific treatment strategies for these malignant diseases.
|Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M et al. (2016) Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol 12:876-84|
|Hnisz, Denes; Weintraub, Abraham S; Day, Daniel S et al. (2016) Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science 351:1454-8|
|Akahane, K; Sanda, T; Mansour, M R et al. (2016) HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia 30:219-28|
|Tan, S H; Yam, A W Y; Lawton, L N et al. (2016) TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia. Leukemia 30:959-62|
|Frock, Richard L; Hu, Jiazhi; Meyers, Robin M et al. (2015) Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol 33:179-86|
|Jiang, Wenxia; Lee, Brian J; Li, Chen et al. (2015) Aberrant TCRÎ´ rearrangement underlies the T-cell lymphocytopenia and t(12;14) translocation associated with ATM deficiency. Blood 125:2665-8|
|Mansour, Marc R; Reed, Casie; Eisenberg, Amy R et al. (2015) Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Br J Haematol 168:230-8|
|Oldridge, Derek A; Wood, Andrew C; Weichert-Leahey, Nina et al. (2015) Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature 528:418-21|
|Kwiatkowski, Nicholas; Zhang, Tinghu; Rahl, Peter B et al. (2014) Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511:616-20|
|Chipumuro, Edmond; Marco, Eugenio; Christensen, Camilla L et al. (2014) CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159:1126-39|
Showing the most recent 10 out of 58 publications